Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. director Kimberly Ann Box received a grant of stock options on Class A Common Stock. The award covers 77,586 options with an exercise price of $1.39 per share and no upfront purchase cost. These options vest in full, subject to her continued service, on the earlier of the first anniversary of the June 2, 2026 grant date or the company’s next annual shareholder meeting, and expire on June 2, 2036. Following this grant, she holds 77,586 derivative securities directly through this option award.
Cibus, Inc. director Craig Wichner received a grant of stock options covering 77,586 shares of Class A common stock. The options have an exercise price of $1.39 per share and expire on June 2, 2036.
According to the award terms, the options vest in full if the director continues to serve until the earlier of the first anniversary of the grant date or the company’s next annual meeting of shareholders. After this grant, Wichner holds 77,586 derivative securities tied to the company’s stock, reflecting routine equity-based director compensation rather than an open-market purchase or sale.
Urban Thomas reported acquisition or exercise transactions in this Form 4 filing.
Cibus, Inc. director Urban Thomas received an equity award of 64,748 shares of Class A Common Stock at no purchase price, as reflected in a Form 4 insider filing. The award is in the form of Restricted Stock Units that vest in full, subject to his continued service, on the earlier of the first anniversary of the grant date or the date of the company’s next annual meeting of shareholders. Following this grant, Thomas is reported as directly holding 64,748 shares.
Cibus, Inc. is registering 10,738,040 shares of Class A Common Stock issuable upon exercise of outstanding warrants.
This prospectus covers the issuance of those shares upon warrant exercise and states that the Company will receive proceeds from such exercises. The prospectus discloses assumed share counts of 76,345,736 shares outstanding as of March 31, 2026 and presents dilution and tax-related information, including a net tangible book value (deficit) of $(228.3) million, or $(2.99) per share as of March 31, 2026. The Company states it intends to use net proceeds, if any, for working capital and to fund development of its Rice weed management traits.
Cibus, Inc. is offering up to $50,000,000 of Class A Common Stock in an at-the-market program pursuant to a Sales Agreement with Jefferies LLC.
The offering permits Cibus to sell shares from time to time through Jefferies as agent, with Jefferies receiving a 3.0% commission. Net proceeds are intended for working capital and general corporate purposes, including further development of Rice herbicide tolerance traits and facilities-related costs.
Cibus, Inc. filed a shelf registration to offer up to $200,000,000 of securities and a prospectus supplement establishing an at-the-market program to sell up to $50,000,000 of Class A common stock through Jefferies.
The supplement notes 10,738,040 shares of Class A Common Stock from a prior registration were included as Unsold Securities pursuant to Rule 415(a)(6). The prospectus discloses 76,331,634 shares of Class A Common Stock outstanding as of May 8, 2026, cash of $30.3 million as of March 31, 2026, and management’s statement that additional financing will be needed to address going-concern risk.
Cibus, Inc. reported first-quarter 2026 revenue of $1.7 million, up from $1.0 million a year earlier, mainly from collaboration work in sustainable ingredients. Net loss narrowed to $21.2 million from $49.4 million, helped by lower research, selling, and litigation costs and no goodwill impairment this year.
Cash and cash equivalents rose to $30.3 million as of March 31, 2026, after two equity offerings that brought in about $33.4 million of net proceeds. The company used $11.5 million of cash in operating activities in the quarter and targets annual net cash usage of about $30 million or less in 2026.
Management discloses substantial doubt about Cibus’ ability to continue as a going concern over the next year without new capital. A large related-party Royalty Liability of $244.0 million, carrying a 16.5% effective yield and generating $9.1 million of quarterly interest expense, continues to weigh on results as the company remains pre-royalty and pre-profit.
Cibus, Inc. reported first quarter 2026 results showing higher revenue and a significantly smaller loss while advancing key agricultural trait programs. Revenue for the quarter ended March 31, 2026 was $1.7 million, up from $1.0 million a year earlier, reflecting progress across programs.
Research and development expense fell to $8.7 million and SG&A to $5.1 million, helped by cost reduction initiatives and the absence of a $21.0 million goodwill impairment recorded in the prior-year quarter. Net loss narrowed to $21.2 million from $49.4 million, and net loss per share improved to $0.33 from $1.34.
Cash and cash equivalents rose to $30.3 million as of March 31, 2026, supported by two equity offerings raising $22.3 million and approximately $15.0 million in gross proceeds. The company expects existing cash to fund planned operations into late in the first quarter of 2027 while it moves its Rice herbicide tolerance and Sustainable Ingredients programs toward commercialization.
FMR LLC reports beneficial ownership of 11,425,929 shares of Cibus Inc. Class A common stock, representing 15.0% of the class as of 03/31/2026. The filing states that Fidelity Growth Company Commingled Pool holds 5,022,986 shares, or 6.6% as of 03/31/2026.
The schedule discloses sole dispositive power and sole voting power amounts for FMR LLC and notes authorization by Richard Bourgelas under a power of attorney on behalf of FMR LLC and Abigail P. Johnson.